Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mark G. Atherton"'
Autor:
Anthony V. Moorman, Hazel M. Robinson, F W van Delft, Helen Worley, Christine J. Harrison, Sarah Wright, Jonathan C. Strefford, G Bettney, Fiona M. Ross, Vaskar Saha, Teresa Davies, Adam R. M. Stewart, Sandra Hing, Polly Talley, Mike Griffiths, Mark G. Atherton, Kerry E. Barber
Publikováno v:
Oncogene. 26(29)
Chromosomal abnormalities are important for the classification and risk stratification of patients with acute lymphoblastic leukemia (ALL). However, approximately 30% of childhood and 50% of adult patients lack abnormalities with clinical relevance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0275152e463acabc955a3d6a303eb3e1
https://pubmed.ncbi.nlm.nih.gov/17237825
https://pubmed.ncbi.nlm.nih.gov/17237825
Autor:
Florence Nguyen-Khac, Debra M. Lillington, Lana Harder, Theodore Balasas, E. Loraine Karran, Aneela Majid, Stéphanie Struski, Mark G. Atherton, Polly Talley, María José Calasanz, Jonathan C. Strefford, Renata Walewska, Helen Worley, Anne Hagemeijer, Isabelle Radford-Weiss, José I. Martín-Subero, Keiji Sugimoto, Helena Kempski, Melanie J. Welham, Michel Lessard, Takashi Akasaka, Teresa Davies, Sarah Moore, Oskar A. Haas, Christine J. Harrison, David Brown, Claudia Schoch, Reiner Siebert, Monika Brüggemann, Lisa J. Russell, Martin J. S. Dyer, Stefan Gesk, Kelvin Cain
Publikováno v:
Blood. 109(8)
CCAAT enhancer-binding protein (CEBP) transcription factors play pivotal roles in proliferation and differentiation, including suppression of myeloid leukemogenesis. Mutations of CEBPA are found in a subset of acute myeloid leukemia (AML) and in some
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8561485406bdec5f126b0161bfcae4df
https://pubmed.ncbi.nlm.nih.gov/17170124
https://pubmed.ncbi.nlm.nih.gov/17170124
Autor:
Andrew R. Pettitt, Angela Douglas, Anna Burford, Paul D. Sherrington, Anthony Carter, Kevin Pearson, Ke Lin, Mark G. Atherton, Daniel Catovsky, Vasantha Brito-Babapulle, Estella Matutes
Publikováno v:
Blood. 104:953-953
Adverse prognostic factors in CLL include functional impairment of the p53 pathway [Blood2002;100:1404] and the chromosomal aberrations del 17p13, del 11q23 and +12 [reviewed in Leukemia2002;16:993]. Intriguingly, TP53 is deleted at 17p13, ATM (an im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32abae8be434b558da35cf2df376620e
https://doi.org/10.1182/blood.v104.11.953.953
https://doi.org/10.1182/blood.v104.11.953.953